Metformin induces lipid changes on sphingolipid species and oxidized lipids in polycystic ovary syndrome women

27 women with polycystic ovary syndrome (PCOS) confirmed by Rotterdam criteria, mean age 24.7 years. Exclusions: malignant neoplasia, active infectious diseases, anemia, diabetes mellitus, history of ischaemic heart disease, thromboembolism, stroke, and use of antihypertensive or lipid-lowering drugs.

Metformin oral, initiated at 500 mg/day for 2 weeks, increased to 1000 mg/day for weeks 3-4, and 1500 mg/day for weeks 5-12 (total 12 weeks of treatment).

Alterations in the plasma lipidomic profile (low molecular-weight ionizable lipid molecules) after 12 weeks of treatmentsurrogate